Treatment of unresectable skull base meningiomas with somatostatin analogs

Neurosurgical Focus

Volumn 30, Issue 5, 2011, Pages

  Schulz, Chris ^a   Mathieu, René ^a   Kunz, Ulrich ^a   Mauer, Uwe Max ^a  

^a BUNDESWEHRKRANKENHAUS ULM   (Germany)

Author keywords

Hormone therapy; Meningioma; Skull base; Somatostatin

Indexed keywords

DIAGNOSTIC AGENT; DRUG DERIVATIVE; HORMONE; IODINE; PENTETIC ACID; SOMATOSTATIN;

ADULT; ARTICLE; FEMALE; HUMAN; MALE; MENINGIOMA; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; RETROSPECTIVE STUDY; SKULL BASE TUMOR;

ADULT; FEMALE; HORMONES; HUMANS; IODINE ISOTOPES; MAGNETIC RESONANCE IMAGING; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; PENTETIC ACID; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; SKULL BASE NEOPLASMS; SOMATOSTATIN;

EID: 79955716655     PISSN: None     EISSN: 10920684     Source Type: Journal    
DOI: 10.3171/2011.1.FOCUS111     Document Type: Article

References (33)

1. Aichholzer M, Bertalanffy A, Dietrich W, Roessler K, Pfisterer W, Ungersboeck K, et al: Gamma knife radiosurgery of skull base meningiomas. Acta Neurochir (Wien) 142:647-653, 2000.
2. Arena S, Barbieri F, Thellung S, Pirani P, Corsaro A, Villa V, et al: Expression of somatostatin receptor mRNA in human meningiomas and their implication in in vitro antiproliferative activity. J Neurooncol 66:155-166, 2004.
3. Chamberlain MC, Glantz MJ, Fadul CE: Recurrent meningioma: salvage therapy with long-acting somatostatin analogue. Neurology 69:969-973, 2007.
4. Dashti SR, Sauvageau E, Smith KA, Ashby LS: Nonsurgical treatment options in the management of intracranial meningiomas. Front Biosci (Elite Ed) 1:494-500, 2009.
5. De Menis E, Tulipano G, Villa S, Billeci D, Bonfanti C, Pollara P, et al: Development of a meningioma in a patient with acromegaly during octreotide treatment: are there any causal relationships? J Endocrinol Invest 26:359-363, 2003.
6. Dutour A, Kumar U, Panetta R, Ouafik L, Fina F, Sasi R, et al: Expression of somatostatin receptor subtypes in human brain tumors. Int J Cancer 76:620-627, 1998.
7. García-Luna PP, Relimpio F, Pumar A, Pereira JL, Leal-Cerro A, Trujillo F, et al: Clinical use of octreotide in unresectable meningiomas. A report of three cases. J Neurosurg Sci 37: 237-241, 1993.
8. Hayashi M, Chernov M, Tamura N, Izawa M, Muragaki Y, Iseki H, et al: Gamma knife robotic microradiosurgery for benign skull base meningiomas: tumor shrinkage may depend on the amount of radiation energy delivered per lesion volume (unit energy). Stereotact Funct Neurosurg 89:6-16, 2 011.
9. Hildebrandt G, Scheidhauer K, Luyken C, Schicha H, Klug N, Dahms P, et al: High sensitivity of the in vivo detection of somatostatin receptors by 111indium (DTPA-octreotide)-scintigraphy in meningioma patients. Acta Neurochir (Wien) 126:63-71, 1994.
10. Jaffrain-Rea ML, Minniti G, Santoro A, Bastianello S, Tam-burrano G, Gulino A, et al: Visual improvement during octreotide therapy in a case of episellar meningioma. Clin Neurol Neurosurg 100:40-43, 1998.
11. Jagannathan J, Oskouian RJ, Yeoh HK, Saulle D, Dumont AS: Molecular biology of unreresectable meningiomas: implications for new treatments and review of the literature. Skull Base 18:173-187, 2008.
12. Jung HW, Yoo H, Paek SH, Choi KS: Long-term outcome and growth rate of subtotally resected petroclival meningiomas: experience with 38 cases. Neurosurgery 46:567-575, 2000.
13. Koper JW, Markstein R, Kohler C, Kwekkeboom DJ, Avezaat CJ, Lamberts SW, et al: Somatostatin inhibits the activity of adenylate cyclase in cultured human meningioma cells and stimulates their growth. J Clin Endocrinol Metab 74:543-547, 1992.
14. Mirimanoff RO, Dosoretz DE, Linggood RM, Ojemann RG, Martuza RL: Meningioma: analysis of recurrence and progression following neurosurgical resection. J Neurosurg 62:18-24, 1985.
15. Newton HB: Hydroxyurea chemotherapy in the treatment of meningiomas. Neurosurg Focus 23(4):E11, 2007.
16. Nakamura M, Roser F, Michel J, Jacobs C, Samii M: The natural history of incidental meningiomas. Neurosurgery 53: 62-71, 2003.
17. Nakamura M, Roser F, Michel J, Jacobs C, Samii M: Volumetric analysis of the growth rate of incompletely resected intracranial meningiomas. Zentralbl Neurochir 66:17-23, 2005.
18. Patel RC, Kumar U, Lamb DC, Eid JS, Rocheville M, Grant M, et al: Ligand binding to somatostatin receptors induces receptor-specific oligomer formation in live cells. Proc Natl Acad Sci USA 99:3294-3299, 2002.
19. Patel YC: Somatostatin and its receptor family. Front Neuroendocrinol 20:157-198, 1999.
20. Patel YC, Srikant CB: Somatostatin receptors. Trends Endocrinol Metab 8:398-405, 1997.
21. Pistolesi S, Fontanini G, Boldrini L, Camacci T, De Ieso K, Lupi G, et al: The role of somatostatin in vasogenic meningioma associated brain edema. Tumori 89:136-140, 2003.
22. Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al: Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27:4656-4663, 2009.
23. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC: Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 288:154-157, 2000.
24. Rocheville M, Lange DC, Kumar U, Sasi R, Patel RC, Patel YC: Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. J Biol Chem 275:7862-7869, 2000.
25. Rockhill J, Mrugala M, Chamberlain MC: Intracranial meningiomas: an overview of diagnosis and treatment. Neurosurg Focus 23(4):E1, 2 0 07.
26. Rünzi MW, Jaspers C, Windeck R, Benker G, Mehdorn HM, Reinhardt V, et al: Successful treatment of meningioma with octreotide. Lancet 333:1074, 1989 (Letter).
27. Rünzi MW, Jaspers C, Windeck R, Benker G, Mehdorn M, Reinhardt V, et al: Treatment of meningioma with octreotide. Lancet 334:217-218, 1989 (Letter).
28. Schmid HA: Pasireotide (SOM230): development, mechanism of action and potential applications. Mol Cell Endocrinol 286:69-74, 2008.
29. Schmid S, Aboul-Enein F, Pfisterer W, Birkner T, Stadek C, Knosp E: Vascular endothelial growth factor: the major factor for tumor neovascularization and edema formation in meningioma patients. Neurosurgery 67:1703-1708, 2 010.
30. Sioka C, Kyritsis AP: Chemotherapy, hormonal therapy, and immunotherapy for recurrent meningiomas. J Neurooncol 92: 1-6, 2009.
31. Wass JA, Lytras N, Besser GM: Somatostatin octapeptide (SMS 201-995) in the medical treatment of acromegaly. Scand J Gastroenterol Suppl 119:136-140, 1986.
32. Wen PY, Quant E, Drappatz J, Beroukhim R, Norden AD: Medical therapies for meningiomas. J Neurooncol 99:365-378, 2010.
33. Zeidman LA, Ankenbrandt WJ, Du H, Paleologos N, Vick NA: Growth rate of non-operated meningiomas. J Neurol 255: 891-895, 2008.